Trials / Withdrawn
WithdrawnNCT05481905
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT Trial: A Randomized, Double-blind, Placebo-controlled Adjunctive Treatment Trial to Evaluate the Efficacy and Safety of ENX-101 in Patients With Focal (Partial Onset) Seizures
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Engrail Therapeutics INC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to 4 antiseizure medications yet still experiencing seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENX-101 | Adjunctive treatment to current antiseizure medication |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-12-01
- First posted
- 2022-08-01
- Last updated
- 2023-07-06
Locations
38 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05481905. Inclusion in this directory is not an endorsement.